Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Equity Average (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Equity Average data on record, last reported at $484.2 million in Q3 2023.

  • For Q3 2023, Equity Average fell 18.67% year-over-year to $484.2 million; the TTM value through Sep 2023 reached $484.2 million, down 18.67%, while the annual FY2022 figure was $480.2 million, 53.5% up from the prior year.
  • Equity Average reached $484.2 million in Q3 2023 per CGEM's latest filing, down from $492.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $595.4 million in Q3 2022 and bottomed at $93.3 million in Q3 2020.
  • Average Equity Average over 4 years is $400.3 million, with a median of $458.1 million recorded in 2021.
  • Peak YoY movement for Equity Average: skyrocketed 384.55% in 2021, then dropped 18.67% in 2023.
  • A 4-year view of Equity Average shows it stood at $144.0 million in 2020, then surged by 202.42% to $435.4 million in 2021, then grew by 28.74% to $560.6 million in 2022, then dropped by 13.63% to $484.2 million in 2023.
  • Per Business Quant database, its latest 3 readings for Equity Average were $484.2 million in Q3 2023, $492.6 million in Q2 2023, and $510.3 million in Q1 2023.